Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA; GELLC Study Group.

Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19.

2.

The utility of multiparametric flow cytometry in the detection of primary effusion lymphoma (PEL).

Galán J, Martin I, Carmona I, Rodriguez-Barbero JM, Cuadrado E, García-Alonso L, García-Vela JA.

Cytometry B Clin Cytom. 2019 Sep;96(5):375-378. doi: 10.1002/cyto.b.21637. Epub 2018 May 10.

PMID:
29669178
3.

Immunomodulatory effect of Polypodium leucotomos (Anapsos) in child palatine tonsil model.

Sánchez-Rodríguez C, Peraza Cruces KR, Rodrigáñez Riesco L, García-Vela JA, Sanz-Fernández R.

Int J Pediatr Otorhinolaryngol. 2018 Apr;107:56-61. doi: 10.1016/j.ijporl.2018.01.030. Epub 2018 Jan 31.

PMID:
29501312
4.

Minimal residual disease in chronic lymphocytic leukaemia.

García Vela JA, García Marco JA.

Med Clin (Barc). 2018 Feb 23;150(4):144-149. doi: 10.1016/j.medcli.2017.06.067. Epub 2017 Aug 31. Review. English, Spanish.

PMID:
28864095
5.

Prostatic-Like Syndrome in a Woman with Chronic Lymphocytic Leukemia: Sequential Kinase Inhibitor Therapy.

Velasco-Rodríguez D, Piris-Villaespesa M, Soteras C, Vallés A, García-Marco JA, García-Vela JA.

Case Rep Hematol. 2017;2017:3869020. doi: 10.1155/2017/3869020. Epub 2017 Jul 2.

6.

Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy.

Marquet J, Velazquez-Kennedy K, López S, Benito A, Blanchard MJ, Garcia-Vela JA.

Hematol Oncol. 2018 Feb;36(1):316-319. doi: 10.1002/hon.2445. Epub 2017 Jun 4.

PMID:
28580733
7.

CD105 expression in early erythroid precursors.

García-Vela JA, Martin Rubio I, Marquet J, Alvarez Juarez MA.

Am J Hematol. 2017 Aug;92(8):E155-E156. doi: 10.1002/ajh.24763. Epub 2017 Jun 1. No abstract available.

8.

Skin lesions and cytological features in HTLV-1 associated adult T-cell leukaemia/lymphoma.

Marquet J, Piris-Villaespesa M, Rodriguez E, López S, Villarrubia J, García-Vela JA.

Br J Haematol. 2017 May;177(4):507. doi: 10.1111/bjh.14600. Epub 2017 Mar 14. No abstract available.

PMID:
28295186
9.

Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.

Lozano-Santos C, García-Vela JA, Pérez-Sanz N, Nova-Gurumeta S, Fernandez-Cuevas B, Gomez-Lozano N, Sánchez-Beato M, Sanchez-Godoy P, Bueno JL, Garcia-Marco JA.

Leuk Lymphoma. 2017 Apr;58(4):859-865. doi: 10.1080/10428194.2016.1213829. Epub 2016 Aug 8.

PMID:
27499002
10.

The use of adipose mesenchymal stem cells and human umbilical vascular endothelial cells on a fibrin matrix for endothelialized skin substitute.

Sánchez-Muñoz I, Granados R, Holguín Holgado P, García-Vela JA, Casares C, Casares M.

Tissue Eng Part A. 2015 Jan;21(1-2):214-23. doi: 10.1089/ten.TEA.2013.0626. Epub 2014 Aug 19.

PMID:
25007712
11.

Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.

Lozano-Santos C, Martinez-Velasquez J, Fernandez-Cuevas B, Polo N, Navarro B, Millan I, Garcia JM, Collado R, Sanchez-Godoy P, Carbonell F, Garcia-Vela JA, Garcia-Marco JA, Gomez-Lozano N.

PLoS One. 2014 Jun 27;9(6):e101063. doi: 10.1371/journal.pone.0101063. eCollection 2014.

12.

Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.

Weitz I, Meyers G, Lamy T, Cahn JY, Uranga MT, García Vela JA, Sanz MA, Severino B, Kelly RJ, Hillmen P, Hill A.

Intern Med J. 2013 Mar;43(3):298-307. doi: 10.1111/j.1445-5994.2012.02924.x.

PMID:
22909078
13.

Hairy cell leukemia, blastic type: description of spleen morphology and immunophenotype of a distinctive case.

Kanellis G, Garcia-Alonso L, Camacho FI, Garcia JF, Mollejo M, Montes-Moreno S, Garcia-Vela JA, Piris MA.

Leuk Lymphoma. 2011 Aug;52(8):1589-92. doi: 10.3109/10428194.2011.575488. Epub 2011 May 3. No abstract available.

PMID:
21534875
14.

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.

Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; Spanish Group for the Study of CNS Disease in NHL.

Eur J Haematol. 2010 Oct;85(4):321-8. doi: 10.1111/j.1600-0609.2010.01478.x. Epub 2010 Jul 28.

PMID:
20528905
15.

Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.

Garcia-Marco JA, Panizo C, Garcia ES, Deben G, Alvarez-Larran A, Barca EG, Sancho JM, Penarrubia MJ, Garcia-Cerecedo T, Garcia Vela JA.

Cancer. 2009 May 1;115(9):1892-8. doi: 10.1002/cncr.24204.

16.

Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain.

Sancho JM, Morgades M, Alonso N, Deben G, Fernández de Sevilla A, Vázquez L, Nicolás C, García Vela JA, Arranz R, Abella E, Canales MA, Miralles P, Sánchez E, Hermosilla M, Conde E, Rueda A, Ribera JM; investigators of QUIT Study (PETHEMA, GELTAMO and GOTEL Groups).

Med Clin (Barc). 2008 Oct 11;131(12):441-6.

PMID:
18928733
17.

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.

Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).

Eur J Haematol. 2008 Mar;80(3):227-35. Epub 2007 Dec 18.

PMID:
18088400
18.

Flow cytometric DNA analysis on fine needle aspiration biopsies of liver lesions.

Granados R, García-Vela JA, Fenández-Segoviano P, Aramburu JA, Martín I, Murillo N, Camarmo E, De La Cal MA.

Cytopathology. 2002 Oct;13(5):273-83.

PMID:
12421443
19.

Comparative intracellular cytokine production by in vitro stimulated T lymphocytes from human umbilical cord blood (HUCB) and adult peripheral blood (APB).

García Vela JA, Delgado I, Bornstein R, Alvarez B, Auray MC, Martin I, Oña F, Gilsanz F.

Anal Cell Pathol. 2000;20(2-3):93-8.

20.

Aberrant immunophenotypes detected by flow cytometry in acute lymphoblastic leukemia.

García Vela JA, Monteserin MC, Delgado I, Benito L, Oña F.

Leuk Lymphoma. 2000 Jan;36(3-4):275-84.

PMID:
10674899
21.

Myeloperoxidase detection by three-color flow cytometry in acute lymphoblastic leukemia.

García Vela JA, Delgado I, Oña F.

Am J Clin Pathol. 1999 Jul;112(1):122-4. No abstract available.

PMID:
10396294
22.

Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-), and CD33(-).

García Vela JA, Martin M, Delgado I, García Alonso L, Monteserin MC, Benito L, Somolinos N, Oña F.

Ann Hematol. 1999 May;78(5):237-40.

PMID:
10391105
23.

Pure red cell aplasia associated with large granular lymphocytic leukemia: a rare association in Western countries.

García Vela JA, Pérez V, Monteserin MC, Oña F.

Haematologica. 1998 Jul;83(7):664-5.

24.

Detection of minimal residual disease in B-cell chronic lymphocytic leukaemia by flow cytometry.

García Vela JA, Delgado I, García Alonso L, Monteserin MC, Benito L, Oña F, Lastra AM.

Br J Haematol. 1997 Nov;99(2):464-5. No abstract available.

PMID:
9375774
25.

Pure red cell aplasia and cyclosporine.

Garcia Vela JA, Pontes MJ, Monteserin MC, Oña F, Lastra AM, Pérez V, Gilsanz F.

Am J Hematol. 1995 Jun;49(2):172-3. No abstract available.

PMID:
7771475
26.

Autoimmune thrombocytopenia after autologous bone marrow transplantation.

Garcia Vela JA, Oña F, Monteserin MC, Lastra AM, Garcia Laraña J, Lopez J, Perez Oteyza J, Odriozola J.

Am J Hematol. 1994 Aug;46(4):375. No abstract available.

PMID:
8037199
27.

Cyclosporin A for Diamond-Blackfan anemia: a new case.

Monteserin MC, Garcia Vela JA, Oña F, Lastra AM.

Am J Hematol. 1993 Apr;42(4):406-7. No abstract available.

PMID:
8493997
28.

Cyclosporine A used as a single drug in the treatment of pure red cell aplasia associated with thymoma.

Garcia Vela JA, Monteserin MC, Oña F, Barea LM, Lastra A, Pérez V.

Am J Hematol. 1993 Feb;42(2):238-9. No abstract available.

PMID:
8438895
29.

[Late post-transfusional hemolysis caused by anti-Kidd-b].

García Vela JA, Menor MD, Blanco L, Lastra AM.

Sangre (Barc). 1992 Jun;37(3):208-9. Spanish. No abstract available.

PMID:
1440102
30.

[Interleukin-6 and multiple myeloma].

García Vela JA.

Med Clin (Barc). 1992 May 9;98(18):718. Spanish. No abstract available.

PMID:
1602889
31.

[A multisecretory pancreatic tumor and associated hypouricemia].

Gato Díez A, Gaspar Alonso-Vega G, García Vela JA, Montans Araujo J.

Med Clin (Barc). 1992 Jan 25;98(3):118-9. Spanish. No abstract available. Erratum in: Med Clin (Barc) 1992 Mar 28;98(12):464.

PMID:
1313128

Supplemental Content

Loading ...
Support Center